NATCO Pharma Limited (NATCOPHARM)
Healthcare | Drug Manufacturers - Specialty & Generic
₹1262.85
1.60% (₹19.85)
Market Overview
| Market Cap | 226252193792 |
| Volume | 435516 |
| 52W High | ₹1639.0 |
| 52W Low | ₹828.0 |
Key Ratios
| P/E Ratio | 11.624171 |
| EPS | 108.64 |
| Beta | 0.519 |
| Dividend Yield | 0.0046% |
Financial Performance
Revenue Growth
0.329%
Profit Margin
0.42613998%
ROE
0.31228%
ROA
0.18889%
Stock Analysis Score: 80/100
Growth Score: 80/100
Key Strengths:
- Excellent profit margins above 15%
- Strong ROE above 15%
- Attractive PE ratio below 15
- Low volatility with beta below 1
- Strong operating margins above 15%
Recommendation
Strong Buy - The stock shows excellent fundamentals across multiple metrics
Detailed Analysis
Growth: 0.3% revenue growth indicates weak business expansion.
Profitability: 42.6% profit margin shows excellent operational efficiency.
Returns: ROE of 31.2% demonstrates strong return on shareholder investment.
Valuation: PE ratio of 11.6x is attractive compared to market averages.
Trading Decision Guide
- Score 80-100: Consider for long-term investment with high conviction
- Score 60-79: Suitable for medium-term investment with regular monitoring
- Score 40-59: Short-term trading opportunities, maintain strict stop-losses
- Score Below 40: High-risk trading only, thorough research essential
Risk Factors
- Market Cap: ₹22625.2Cr
- Beta: 0.52 (Market Volatility)
- 52-Week Range: ₹828.0 - ₹1639.0
Last Updated: 2025-01-23 06:56:29